Phencyclidine (PCP) & Mephedrone
Phencyclidine (PCP), often referred to as "angel dust," is a dissociative anesthetic that exerts its effects primarily through its interaction with the central nervous system. It was originally developed as a surgical anesthetic but was discontinued due to severe psychiatric side effects. The pharmacological action of PCP is complex, involving multiple neurotransmitter systems and ion channels, which contribute to its potent psychoactive and dissociative effects.
At its core, PCP functions as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptor that plays a critical role in synaptic plasticity, memory, and cognition. By binding to a site within the receptor's ion channel, PCP blocks the normal flow of calcium and sodium ions into the neuron, effectively inhibiting excitatory neurotransmission. This disruption in glutamatergic signaling is central to PCP's ability to induce dissociation, hallucinations, and altered perceptions of reality.
In addition to NMDA receptor antagonism, PCP interacts with other receptor systems. It exhibits affinity for dopamine transporters, leading to an increase in extracellular dopamine levels in brain regions such as the striatum and prefrontal cortex. This dopaminergic activity contributes to the drug's stimulating and euphoric properties as well as its potential for addiction. PCP also affects the sigma-1 receptor, a protein involved in modulating neuroplasticity and stress responses, which may amplify its dissociative and hallucinogenic effects.
Moreover, PCP influences other neurotransmitter systems, including acetylcholine, norepinephrine, and serotonin, by either modulating their receptors or affecting their release. These interactions create a wide range of physiological and psychological effects, such as analgesia, tachycardia, hypertension, and profound alterations in mood and cognition.
Pharmacokinetically, PCP is highly lipophilic, allowing it to cross the blood-brain barrier easily and accumulate in fatty tissues. It is metabolized primarily in the liver by the cytochrome P450 enzyme system and is excreted through urine. The drug's half-life varies widely depending on the dose and individual metabolism but can extend for several days, contributing to prolonged effects and detection in the body.
Mephedrone, chemically known as 4-methylmethcathinone, is a synthetic stimulant belonging to the class of substituted cathinones. It produces effects similar to those of amphetamines and MDMA (ecstasy) by acting on the central nervous system, primarily targeting monoamine neurotransmitter systems. Mephedrone exerts its psychoactive and stimulant effects by increasing the activity of dopamine, serotonin, and norepinephrine, which are key neurotransmitters involved in mood, arousal, and reward.
Mephedrone functions as a monoamine reuptake inhibitor and releaser. It binds to the dopamine transporter (DAT) and serotonin transporter (SERT), blocking the reuptake of these neurotransmitters into presynaptic neurons. This inhibition leads to an accumulation of dopamine and serotonin in the synaptic cleft, intensifying their signaling. Additionally, mephedrone promotes the release of these neurotransmitters from storage vesicles within presynaptic neurons into the synapse. This dual action results in heightened dopaminergic and serotonergic activity, which underlies its euphoric, energizing, and empathogenic effects.
The increased dopamine levels primarily contribute to feelings of pleasure, stimulation, and enhanced focus, as dopamine plays a central role in the brain’s reward system. Elevated serotonin activity is associated with mood enhancement, emotional openness, and sensory distortions, which are often described as feelings of empathy or sociability. Norepinephrine, which is also affected by mephedrone, enhances alertness, heart rate, and blood pressure, accounting for the physical stimulation and sympathetic nervous system activation observed during its use.
Mephedrone is metabolized in the liver, primarily by the cytochrome P450 enzyme system. Its metabolites are excreted via urine.
Combining phencyclidine (PCP) and mephedrone poses significant health risks due to their potent and overlapping effects on the central nervous system. Both drugs can elevate heart rate and blood pressure, increasing the risk of cardiovascular complications. The stimulant properties of mephedrone may exacerbate the psychomimetic effects of PCP, potentially leading to severe agitation, paranoia, and hallucinations. Additionally, the combination may impair cognitive and motor functions more profoundly than either drug alone, increasing the likelihood of accidents or injuries.
While specific studies on the combined effects of PCP and mephedrone are limited, research on similar drug combinations suggests heightened risks. For instance, combining stimulants with dissociative anesthetics can lead to increased neurotoxicity and a higher potential for addiction. Users may also experience severe psychological effects, including panic attacks, and psychosis.
Based on the known pharmacological profiles of PCP and mephedrone, their concurrent use is strongly discouraged due to the potential for severe and unpredictable adverse effects.
All things considered, we recommend avoiding this combination.
Last edited by a moderator: